Promising Alzheimer’s drugs are
ready for late-stage clinical trials

Virtually all adults with Ds develop the neuropathology (amyloid beta plaques and tau tangles) consistent with Alzheimer’s by their 40s. At age 40, 10% already have Alzheimer’s dementia. Without necessary resources, Pharma will not be able to measure how well any therapies work for people with Down syndrome and will delay the initiation of late stage clinical trials in Down syndrome with their promising Alzheimer’s therapies.

Progress: 64%

Alzheimer’s Assessment Scales

Grant: $100,000 | Raised: $64,000

Progress: 80%

Clinical Trial Network of Clinicians

Grant: $125,000 | Raised: $100,000

Your Donation Helps

Down syndrome research offers opportunities for people of all ages with Down syndrome. Your support is essential to finding safe, effective drugs and interventions to improve health and independence. Your gift is crucial to furthering these breakthroughs.

We’ve designed a clear path to therapies

Based on recent scientific findings, our CEO, board and world renowned scientific advisors have established four priorities for funding research. We’re focused on exciting research targeting the root cause with the objective of improving health and independence for our loved ones throughout their lifetimes. Our four priorities are: preventing Alzheimer’s onset, improving cognition, developing gene therapies, and advancing understanding.

LuMind RDS News

New Lumind CEO Focusing on Research as a Key to Independence: Part III of III

LuMind’s Laser Focus on Research Hillerstrom knows that given the range of symptoms of those with Down syndrome, a one-size-fits-all approach does not work for early intervention, inclusion, or research. “In theory, current cutting-edge research can help overcome independence obstacles, either symptomatically, or by going after the root cause. I believe that it is important …

Read More

Get ready for Alzheimer’s clinical trials. It’s time.

Join us, we’re stepping up!         Pharma has promising therapies targeting the accumulation of amyloid and tau — two of the characteristics shared by Down syndrome and Alzheimer’s disease — ready for late-stage clinical trials. We are making sure our loved ones with Down syndrome are included in upcoming clinical trials. In …

Read More

LuMind RDS Awards $1.64 Million to Fund Ten Ground-breaking Down Syndrome Research Projects at Top Institutions

New Awards Broaden Funding to New Academic Research Partners Marlborough, MA – July 17, 2017 – LuMind Research Down Syndrome Foundation (LuMind RDS) awards $1,639,000 through 2018 to fund ten Down syndrome research projects in world-renowned Down syndrome research centers and to further develop a research pipeline in Four Scientific Research Categories: 1) Prevent Alzheimer …

Read More

What people are saying about us.

“I never thought I would be in a position to say, ‘We are going to take therapies forward to directly treat Down syndrome.’ Now I think that is the case. We really are in the early stages of a revolution in understanding the basis for many of the features that occur in Down syndrome.”

Dr. Roger Reeves, Johns Hopkins